Tamoxifen citrate 20 - Hilma Biocare

Tamoxifen citrate was created in 1962 by Imperial Chemical Industries (ICI) initially explored for its potential, in addressing female infertility concerns with an advancement seen in 1971 during trials connecting its efficacy to the treatment of breast cancer patients. By 1977, it had been FDA-approved for breast cancer, particularly targeting estrogen receptor-positive cases. Marketed under the brand Nolvadex, tamoxifen soon became the most widely used anti-estrogen, and remains highly favored by athletes and bodybuilders for controlling estrogen levels during steroid use.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tamoxifen citrate 20 by Hilma Biocare, consult with your doctor or healthcare professional.